A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Public ClinicalTrials.gov record NCT01721746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Study identification
- NCT ID
- NCT01721746
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 405 participants
Conditions and interventions
Conditions
Interventions
- BMS-936558 Biological
- Dacarbazine Drug
- Carboplatin Drug
- Paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2012 (Actual)
- Primary completion
- Feb 16, 2016 (Actual)
- Completion
- Dec 29, 2020 (Actual)
- Last update posted
- Apr 19, 2022
2012 – 2020
United States locations
- U.S. sites
- 32
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92093 | — |
| The Angeles Clinic & Research Institute | Los Angeles | California | 90025 | — |
| University Of California - Los Angeles | Los Angeles | California | 90095 | — |
| San Francisco Oncology Associates | San Francciso | California | 94115 | — |
| UCSF Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Orlando Health, Inc | Orlando | Florida | 32806 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University Of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Allina Health | Minneapolis | Minnesota | 55407 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| MSKCC Clinical Laboratory at Nassau | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University Hospitals | Cleveland | Ohio | 44106 | — |
| Providence Oncology And Hematology | Portland | Oregon | 97213 | — |
| Network Office of Research and Innovation | Allentown | Pennsylvania | 18103 | — |
| St. Luke'S Health System | Allentown | Pennsylvania | 18109 | — |
| Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01721746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2022 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01721746 live on ClinicalTrials.gov.